A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.

Published in: Gut and liver (2022)

for managing typical symptoms in patients with NERD (ClinicalTrial.gov identifier: NCT03928470).

Keyphrases